Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2012-12-03 Director's Dealing
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2012-12-03 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 13, 2012. It announces the completion of target enrollment for a clinical study (phase 3) of a drug, ARIKACE, and includes a press release as an exhibit. The content is an event update rather than a financial report or detailed earnings release. The document length is short (2265 characters), and it primarily serves as a current report on a specific event, not a full financial or management report. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories like earnings releases or annual reports.
2012-11-13 English
SC 13G/A Filing
Major Shareholding Notification
2012-11-13 English
3 Filing
Director's Dealing
2012-11-09 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2012. It announces the appointment of a new Chief Financial Officer, Andrew Drechsler, including details about his employment agreement, compensation, and severance terms. The key section is Item 5.02, which relates to the departure and appointment of directors or certain officers. There are no financial statements or earnings data presented, nor is this a report of voting results or a regulatory certification. The document is clearly an announcement of a management change, specifically the appointment of a new CFO and related employment terms. Therefore, it fits the category of Board/Management Information (MANG). The document length is over 6,000 characters and contains substantive detail about the management change, not just a brief notice or a report publication announcement.
2012-11-07 English
10-Q Filing
Interim / Quarterly Report Q3 2012
2012-11-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.